跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2010-024394-39-BE
EUCTR2010-024394-39-BE进行中（未招募）1 期

A Phase II study of orally administered BEZ235 monotherapy in patients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathway

ovartis Pharma Services AG0 个研究点目标入组 120 人开始时间: 2011年3月28日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
120
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • •Patients eligible for inclusion in this study have to meet all of the following criteria:
  • •1.Patient has provided a signed molecular screening and study Informed Consent Form prior to any screening procedure
  • •2.Patient is a female = 18 years of age on the day of consenting to the study (including molecular screening consent)
  • •3.Patient has a histologically and/or cytologically confirmed diagnosis of breast cancer presenting with metastatic disease that is
  • •hormone receptor positive (based on most recently analyzed biopsy, as documented by a local laboratory); hormone positivity is defined as estrogen receptor and/or progesterone receptor positive, and
  • •human epidermal growth factor receptor 2 (HER2) negative, as documented by a negative CISH/FISH test or an IHC status of 0, 1+ or 2+ (if IHC 2+, a negative FISH/CISH test is required) (based on most recently analyzed biopsy, as documented by a local laboratory)
  • •4.Patient has a known PI3K activation status (defined by PIK3CA mutation and PTEN mutation/expression) prior to start of treatment and has a PI3K activation status of a stratification group enrolling at the time of start of treatment. For this either most recent archival tissue (preferably: one block or a minimum of 20 unstained slides) or fresh formalin fixed tumor sample is mandatory and must be sent to Novartis or a central laboratory designated by Novartis.
  • •5.Patient has received for metastatic breast cancer at least one prior line of endocrine therapy and at least two and no more than three prior lines of chemotherapy.
  • •Note: A chemotherapy line in metastatic disease is an anticancer regimen that contains at least one cytotoxic chemotherapy agent or a targeted therapy.
  • •If a regimen (endocrine or chemotherapy) was discontinued for a reason other than disease progression and lasted less than 21 days, then this regimen does not count as a prior line.
  • •Prior adjuvant endocrine or chemotherapy will be counted as a prior line for metastatic disease only if the patient had progressed while on adjuvant endocrine or chemotherapy or within 12 months after the last administration of the respective therapy. Sequential neoadjuvant/adjuvant therapy will be counted as one regimen.
  • •6.Patient has recovered (to grade = 1) from all clinically significant toxicities related to prior antineoplastic therapies with the exception of alopecia and bone marrow and organ functions (described separately).
  • •7.Patient has objective and radiologically confirmed progression of disease.
  • •8.Patient has at least one measurable lesion as per RECIST.
  • •9.Patient has an Eastern Cooperative Oncology Group (ECOG) performance status = 2, which is not declining during the last 2 weeks before the signature of the main study Informed Consent Form (S-ICF).
  • •10.Patient has adequate bone marrow and organ function as shown by:
  • •Absolute neutrophil count (ANC) = 1.0 x 109/L
  • •Platelets = 100 x 109/L
  • •Hemoglobin (Hgb) = 9.0 g/dL
  • •Serum creatinine = 1.5 x ULN
  • •Total serum bilirubin = 1.5 x ULN (in patients with known Gilbert Syndrome, a total bilirubin = 3.0 x ULN, with direct bilirubin = 1.5 x ULN)
  • •AST and ALT = 3 x ULN (or = 5.0 x ULN if hepatic metastases are present)
  • •Fasting plasma glucose (FPG) = 140mg/dL [7.8 mmol/L]
  • •HbA1c = 8 %
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this

排除标准

  • •1.Patient has received previous treatment with PI3K and/or mTOR inhibitors
  • •2.Patient has active uncontrolled or symptomatic CNS metastases
  • •3.Patient has a concurrent malignancy or has had a malignancy in the last 3 years prior to start of study treatment (with the exception of adequately treated basal or squamous cell carcinoma or cervical carcinoma in situ).
  • •4.Patient has received wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) = 28 days or limited field radiation for palliation = 14 days prior to starting study drug or has not recovered from side effects of such therapy.
  • •5.Patient has had major surgery within 28 days prior to starting study drug or has not recovered from major side effects of the surgery.
  • •6.Patient has active cardiac disease
  • •7.Patient has a history of cardiac dysfunction
  • •8.Family history of congenital long or short QT, or known history of QT/QTc prolongation or Torsades de Pointes (TdP).
  • •9.Inadequately controlled hypertension (i.e., SBP>180 mmHg or DBP>100mmHg).
  • •10.Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BEZ235 (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea grade = 2, malabsorption syndrome or small bowel resection).
  • •11.Patient is concurrently using other approved antineoplastic or any investigational agents (hormonal agent included) in the last 30 days prior to start of treatment.
  • •12.Patient is receiving chronic treatment with systemic steroids or another immuno-suppressive agent at start of study treatment.
  • •13.Patient is being treated at start of study treatment with any of the following drugs:
  • •Drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A4 including herbal medications (see Appendix 1 for a list of prohibited CYP3A4 inhibitors and inducers)
  • •Drugs with a known risk to induce Torsades de Pointes (see Appendix 3 for a list of prohibited drugs)
  • •Warfarin and coumadin analogues
  • •LHRH agonists
  • •14.Patient is consuming Seville oranges, grapefruit, grapefruit hybrids, pummelos and exotic citrus fruits (as well as their juices) during the last 7 days prior to start of treatment. Regular orange juice is permitted.
  • •15.Immunocompromised patients, including known seropositivity for HIV (testing is not mandatory)
  • •16.Patient has other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment contraindicate her participation in the clinical study (e.g. uncontrolled diabetes, chronic pancreatitis, active chronic hepatitis etc.).
  • •17.Patient is not able to understand or to comply with study instructions and requirements or has a history of non-compliance to medical regimen.
  • •18.Patient is a pregnant or nursing (lactating) woman, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum ßhCG laboratory test (> 5 mIU/mL).
  • •19.Patient is a woman of child-bearing potential, defined as a woman physiologically capable of becoming pregnant, including a woman whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using a double barrier method for birth control throughout the trial.

研究者

相似试验

进行中（未招募）
不适用
A Phase II study of orally administered BEZ235 monotherapy in patients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathwaypatients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathwayMedDRA version: 13.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2010-024394-39-GBovartis Pharma Services AG120
进行中（未招募）
不适用
A Phase II study of orally administered BEZ235 monotherapy in patients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathwayPatients who have experienced progression of disease after first-line antineoplasic treatment of advanced endometrial carcinomaMedDRA version: 13.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2010-024394-39-CZovartis Pharma Services AG120
已完成
2 期
A phase II study of orally administered BEZ235 monotherapy in patients with metastatic or unresectable malignant PEComaPerivascular epithelioid cell tumors (PEComa)soft tissue tumor10072990
NL-OMON37195ovartis3
进行中（未招募）
不适用
Safety and efficacy of BEZ235 in patients with perivascular epithelioid cell tumors (PEComas)Adult patient with metastatic or unresectable malignant perivascular epithelioid cell tumors (PEComa)MedDRA version: 14.1Level: PTClassification code 10039491Term: SarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-001884-39-ESovartis Farmaceutica S.A.33
进行中（未招募）
不适用
Safety and efficacy of BEZ235 in patients with perivascular epithelioid cell tumors (PEComas)
EUCTR2011-001884-39-NLovartis Pharma Services AG33